Okuyama Ayako, Takemura Yukie, Sasaki Minako, Higashi Takahiro
Graduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan.
National Cancer Center Institute for Cancer Control, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Support Care Cancer. 2025 Apr 1;33(4):335. doi: 10.1007/s00520-025-09408-7.
Treatment decisions are often highly complex when the outcomes are uncertain. In Japan, the consultation fees incurred can be reimbursed when physicians and nurses work together with patients to provide shared decision-making (SDM) on treatment plans. However, the extent to which reimbursed consultations are used by clinicians is unclear. This study aimed to determine the extent to which so-called "reimbursed SDM consultations" are used in cancer treatment and to identify the characteristics of patients having these consultations using a nationwide database.
This retrospective study used health service utilization data linked to hospital-based cancer registries from 591 hospitals in Japan. Data for patients aged 18 years or above diagnosed with cancer in 2019 were analyzed. Multivariable logistic regression analysis was conducted to analyze the association between reimbursed SDM consultations and patient characteristics.
Overall, 74,828 patients (12.2%) received reimbursed SDM consultations in 533 hospitals. The presence of breast cancer (odds ratio (OR) = 2.00), treatment types of radiotherapy (OR = 1.86) and pharmacotherapy (OR = 1.76), and distant metastasis (OR = 1.49) and the invasion of adjacent organs (regional) (OR = 1.47) were positively associated with reimbursed SDM consultations. Cervical (OR = 0.38) and renal cancers (OR = 0.49) were negatively associated with reimbursed SDM consultations.
This study is the first to determine the extent to which reimbursed SDM consultations are used and the characteristics of the patients receiving them. Further studies should investigate the factors influencing the use of reimbursed SDM consultations.
当治疗结果不确定时,治疗决策往往高度复杂。在日本,当医生和护士与患者共同参与治疗方案的共同决策(SDM)时,所产生的咨询费用可以得到报销。然而,临床医生对报销咨询的使用程度尚不清楚。本研究旨在确定所谓的“报销式SDM咨询”在癌症治疗中的使用程度,并利用全国性数据库确定接受这些咨询的患者的特征。
这项回顾性研究使用了与日本591家医院的医院癌症登记处相关联的医疗服务利用数据。分析了2019年诊断为癌症的18岁及以上患者的数据。进行多变量逻辑回归分析,以分析报销式SDM咨询与患者特征之间的关联。
总体而言,533家医院的74828名患者(12.2%)接受了报销式SDM咨询。乳腺癌(优势比(OR)=2.00)、放疗(OR=1.86)和药物治疗(OR=1.76)的治疗类型、远处转移(OR=1.49)和邻近器官(区域)侵犯(OR=1.47)与报销式SDM咨询呈正相关。宫颈癌(OR=0.38)和肾癌(OR=0.49)与报销式SDM咨询呈负相关。
本研究首次确定了报销式SDM咨询的使用程度以及接受此类咨询的患者的特征。进一步的研究应调查影响报销式SDM咨询使用的因素。